A main criterion to identify malaria vaccine candidates is the proof that acquired immunity against them is associated with protection from disease. The age of the studied individuals, heterogeneous malaria exposure, and assumption of the maintenance of a baseline immune response can confound these associations.
Since 2007, many efforts have been focused on malaria elimination, with many settings reporting a dramatic decline in malaria cases. A highly efficacious vaccine could supplement the waning naturally acquired immunity (NAI) against malaria in these areas. Given the limited protection conferred by RTS,S vaccination [1] , second-generation vaccines are an urgent requirement. A crucial criterion to identify malaria vaccine candidates is not only the validation of a specific antigen as target of NAI but also the confirmation that this immune response is associated with reduced risk of disease in the target population.
Importantly, malaria cases are not equally distributed in endemic countries. This geographical disparity is observed at all transmission levels [2] [3] [4] and can be as pronounced as between households in the same village [4] . Variations in local transmission intensity and differential mosquito attraction seem to be major reasons for this heterogeneity in malaria exposure [5] . This phenomenon has major implications when studying correlates of protection, because unexposed individuals can be erroneously considered as protected [5, 6] . In fact, inconsistent results are commonly found in the literature, where antibodies against the same antigen in similar populations are differentially associated with protection [7] [8] [9] [10] [11] [12] [13] . These discrepancies might be partially explained by the confounding effect of heterogeneous malaria exposure, together with the age of the studied population, as shown by several studies highlighting the role of age in protective immunity [14] .
Previous approaches to account for heterogeneous malaria exposure are mainly focused on excluding malaria-unexposed individuals from the analyses [15] [16] [17] . Blood-stage infection at any time during the follow-up is the most common indicator of exposure. However, this methodology is logistically costly and is largely used in short-term follow-ups, given that it requires active case detection (ACD) [15] . Besides, it frequently implies the case treatment, limiting the identification of correlates of protection from symptomatic disease. For long-term follow-ups, in addition to blood-stage infection, clinical episodes have also been used as an exposure indicator [17] . However, even focusing the analyses in those individuals reporting an infection and/ or clinical episode during the follow-up, the microheterogeneity in the exposure level can affect the rate of immunity acquisition and consequently the identification of protective correlates. Therefore, it is not only important to focus the analyses on malaria-exposed individuals, but also to consider the exposure level, indicated by serology, clinical or demographic data. Similarly, results from longitudinal studies can also be confounded by the long follow-ups during which the outcome can occur, according to the assumption that the immune responses at baseline represent a stable measure of immune competence [6] . Hence, the follow-up of a longitudinal study can be higher than the actual time that the specific antibodies remain in blood, at least, at protective levels [6, 18] . Approaches to control these phenomena are thought to contribute to a deeper understanding of NAI against vaccine candidates.
We hypothesized that correlates of protection are better identified when studying only malaria-exposed individuals, when limiting the follow-up time according to the antibodies' decay and in older compared to younger children. To address this, we analyzed antibody responses and their functionality to Plasmodium falciparum antigens and assessed the association with clinical malaria risk in Mozambican children. The antigens studied are expressed during pre-erythrocytic and erythrocytic stages, including erythrocyte-binding antigens (EBAs), P. falciparum reticulocyte-binding homologs (PfRhs), merozoite surface proteins (MSPs), and novel antigens scarcely or not tested yet in longitudinal studies, namely, P41, AARP (apical asparagine-rich protein) or CyRPA (cysteine-rich protective asntigen).
METHODS

Study Area and Population
The study was conducted in the Manhiça District, southern Mozambique [19] , where a demographic surveillance system (DSS) provides accurate information on its population (see supplementary methods). Malaria transmission is perennial with some seasonality, coinciding with the rainy season (NovemberApril). P. falciparum and Anopheles funestus are the predominant species and vector, respectively. Entomological inoculation rate in 2002 was 38 infective bites/person/year [19] .
Study population comprised children from three cohorts studied between 2002 and 2007, in placebo-controlled trials (see supplementary methods and [20] [21] [22] ). Children from the placebo arm of each cohort were selected to exclude the effect of any intervention in the acquisition of immunity. Briefly, cohort A [20] involved newborns followed from birth until 2 years of age (cross-sectional visits at 0, 2.5, 5.5, 10.5, 15 and 24 months). Cohort B [22] included children enrolled at 5 months old who underwent cross-sectional visits at 5, 9, 12, and 24 months. Finally, cohort C [21] involved newborns followed from birth until 12 months of age (cross-sectional visits at 0, 3, 9, and 12 months). For cohorts A and C, information about maternal malaria infections (peripheral and placental -acute, chronic, past-) was available, together with maternally-transferred antibodies (measured in cord blood). Infections were detected by microscopy (OM) and malaria episodes by passive case detection (PCD, except for cohort A; see supplementary methods). The National Mozambican and the Hospital Clínic of Barcelona Ethics Review Committees approved these studies. Written informed consent was signed at enrollment. supplementary Table 1 and [23] [24] [25] [26] [27] [28] [29] [30] ). IgG and IgM responses were determined using Luminex xMAP™ beads (see supplementary methods). Briefly, multiplexed beads [31] were incubated with plasma samples, and antibody levels were measured as described elsewhere [31] . Positive, negative, and background controls were added to each plate. Net median fluorescence intensity (MFI) was obtained by subtracting blank values and prior to inter-plate normalization.
Negative MFI values were substituted by the half-value of the minimum positive value for log-transformation.
Functional Assays
In a subset of children with available samples (n = 67), functional features of merozoite-specific antibodies at 24 months were studied. Opsonic phagocytosis (OPA) [32] and complement fixation assays (CFA) [33] are detailed in supplementary methods. Briefly, for OPA, freshly isolated merozoites were ethidium bromide-stained and incubated with plasma samples. THP-1 monocytes were added after opsonization. The number of THP-1 cells with internalized merozoites was determined by flow cytometry, and the ratio to a positive control value was reported as the relative phagocytosis index (RPI%). In CFA, plates were coated with MSP1 19 or MSP3, and plasma samples incubated to allow antibody:antigen recognition. Human C1q was added, detected, and its binding was measured by optic density.
Definitions and Statistical Analysis
Cross-sectional samples were grouped as follows: birth (cohort A and B); 2. . Clinical malaria was defined as axillary temperature ≥37.5º C or reported fever in the preceding 24 hours with positive parasitemia by OM. Children were not considered at risk of malaria after 28 days of reporting an episode.
Seropositive threshold was defined by the mean plus 3 standard deviation of IgG and IgM antibody levels of 82 and 85 Spanish naive donors, respectively. Breadth of antibody responses was determined by the sum of seropositive responses for each child. Malaria-exposed individuals were those that met, at least, one of the following criteria during the follow-up: report a previous P. falciparum infection or clinical episode; being seropositive for IgM levels against the pre-erythrocytic antigens CSP or LSA1; or a mother with reported infection during pregnancy (placental or peripheral).
Parametric or nonparametric tests were applied according to the variables distribution. Wilcoxon rank-sum (or KruskalWallis) and χ 2 tests were used to compare means or prevalence between groups, respectively. Correlation between variables were assessed by Spearman's correlation test.
To study the effect of age and infection on antibody levels, we performed crude and adjusted linear regression models. Cox proportional hazard models were used to calculate hazard ratios (HR) of clinical malaria. To test the hypothesis that protective associations of antibodies differ with age, we compared the HR in children at 9 and 24 months of age during a year of follow-up. To compare the importance of accounting for malaria-exposure heterogeneity, 2 Cox models were estimated: (i) adjusted by infection at sampling, age, sex, neighborhood of residence, and cohort and (ii) limited to malaria-exposed individuals and adjusted by covariates specified in (i) and by exposure variables: IgM levels at sampling against pre-erythrocytic antigens; IgM levels against a mosquito saliva antigen (gSG6-P1) at sampling; and the number of previous malaria episodes. IgM adjustments were not done when analyzing IgM or functional immune responses' association with clinical malaria risk. Hazards proportionality was evaluated by studying the Schoenfeld residuals. The time to 25% of baseline (birth) antibody levels were estimated using linear mixed-effect regression models with data from birth to 5 months from children without infection or clinical episode during that time.
These estimated times were used to limit the follow-up in Cox regression models when indicated.
P-values were corrected by the Benjamini-Hochberg procedure [34] . Statistical analyses were performed using Stata version 14 (StataCorp. College Station, TX, USA) and graphs with Prism7 (GraphPad) and R Core Team (2016, Vienna, Austria).
RESULTS
Antibody Dynamics During the First 2 Years of Life
A total of 1142 samples were tested for IgG and IgM against 23 P. falciparum antigens. Characteristics of children studied in each cross-sectional visit are specified in Table 1 . Maternal IgG antibodies (measured in the newborns) were, in general, lost during the first months up to 5 months of age when the antibody responses increased again. As expected, IgM antibody responses increased since birth (Figure 1 ). Main determinants of antibody levels in children from 5 months old were infection at sampling and age (Supplementary Table 2 ).
Association of Antibody Responses With Risk of Clinical Malaria
Malaria-exposed children represented 84.2% of the studied population at 9 months old (208 out of 247) and 83.1% at 24 months of age (148 out of 178). Malaria-exposed children had higher breadth of IgG and IgM antibody responses at 9 and 24 months old compared to children considered non-exposed (Wilcoxon rank-sum test, P < .001).
In order to identify correlates of protection while studying the importance of accounting for heterogeneous malaria exposure, Cox regression models adjusted by P. falciparum infection, sex, age, neighborhood of residence, and cohort were compared to models estimated after accounting for malaria exposure. At 9 and 24 months of age, initial models showed significant associations of IgG and IgM levels with higher risk of clinical malaria (HR > 1). However, when considering malaria exposure, these associations with increased risk disappeared, and protective associations emerged, only at 24 months of age. (Figure 2 ). The specific antibodies differentially associated with reduced risk at 24 versus 9 months of age were not necessarily higher in the older group, being this the case for IgGs against CyRPA, DBL3X, and DBL5ε (Wilcoxon rank-sum test, P > .050). In contrast, no association of specific IgMs with reduced risk was observed once malaria exposure was considered. Some associations with higher clinical malaria risk were still found (although lost after multiple comparisons correction, Supplementary Figure 1) .
We also hypothesized that limiting the follow-up time according to the antibody's decay would allow to better identify correlates of protection. The time to 25% of baseline levels was calculated for all the specific IgGs ( Figure 3 ). This time ranged from 78 (95% CI [92, 64]; P < .001) for PTRAMP to 550 days (95% CI [397, 703]; P < .001) for P41. These times were used to limit the follow-up time in Cox regression models. As shown in Supplementary Figure 2 , this approach allowed us to decrease the number of significant associations of specific antibodies with higher risk of clinical disease in standard analyses but not when heterogeneity in malaria exposure was considered.
Functional Immune Responses
For a subset of children at 24 months of age (n = 67), we analyzed the capacity of (i) phagocytosis induction by antibodies targeting merozoites and (ii) C1q fixation by MSP 19 and MSP3-specific antibodies. Association of C1q fixation with reduced malaria risk was found only for MSP 19 when considering malaria exposure (HR 0.11 [95% CI 0.02, 0.57]; P = .009; n = 45) but not for MSP3 specific antibodies (HR 0.5 [95% CI 0.2, 1.3); P = .143). MSP1 19 nor MSP3-specific antibodies were associated with protection in this subset (P = .994 and .922, respectively). Their C1q-fixation activity did not correlate for MSP1 19 -specific antibodies, in contrast to antibodies targeting MSP3 (Spearman's rho = 0.37, P < .001 for IgG and rho = 0.212, P = .03 for IgM). RPI increased with increasing breadth of IgG responses (Spearman's rho = 0.47, P-value < .001) and was significantly higher in those children considered exposed compared to those considered nonexposed (Wilcoxon ranksum test, P < .001). However, RPI was not associated with reduced risk of clinical malaria even when considering malaria exposure.
DISCUSSION
In this study, we describe the dynamics of antibody responses against P. falciparum antigens in the first 2 years of life and report correlates of protective immunity in children from Mozambique. This is the first study to our knowledge to point the association of antibodies targeting CyRPA and AARP with reduced malaria risk and to assess functionality of antibody responses in such young children.
Studies restricted to infants are considered less adequate to analyze correlates of protection given the confounding effect of in utero exposure and maternal transferred antibodies. However, this study is focused in children old enough to have lost maternal antibodies and built their own immunity but young enough to still be the target population of routine vaccinations. It is known that antibodies need a mature immune system to perform certain functions [35] , a reason that can explain the lack of protective associations at 9 months compared to 24 months of age, as well as discrepancies with other studies with older children [13, 32, 33] . It is possible that specific antibody levels at 9 months are below protective thresholds [18] , compared to 24 months. The protective threshold can be defined by intrinsic immune system features changing with age, as previously suggested [14] . This observation is in agreement with studies describing higher RTS,S vaccine efficacy in older children [1] . IgGs targeting CyRPA, DBL3x, DBL5ε, EBA140 III-V were associated with reduced clinical malaria risk at 24 months of age, in addition to AARP, DBLα, and P41, that lost significance after multiple comparisons correction. Some of them have already been shown as correlates of protection [13] , but CyRPA and AARP are shown as correlates of protection for the first time. Unexpectedly, association of antibodies against DBL5ε, a VAR2CSA domain that binds to chondroitin sulphate A (CSA), with lower malaria risk was consistently found. P. falciparum-infected erythrocytes binding to CSA was first reported in pediatric isolates [36] , suggesting the possible contribution of CSA-binding to malaria infection and disease in children [37] . However, we cannot discard DBL5ε-specific antibodies as markers of other immune effectors responsible for such observation. We did not identify PfRh5-specific antibodies as correlates of protection, as previously reported [13] . These antibodies can act through the disruption of the PfRh5/CyRPA/Ripr complex [25] , which can be also mediated by CyRPA-specific antibodies. IgM association with higher risk was reduced after accounting for malaria exposure. However, IgM targeting EBA175-PfF2 at 24 months of age was associated with higher clinical malaria risk, which can be explained by mechanisms such as IgM masking [38] . Finally, we report that complement fixation by antibodies targeting MSP1 19 is associated with protection [33] , compared to IgG or IgM levels against MSP1 19 . This confirms previous results where MSP1 19 , but not MSP3, are targets of antibodies fixing complement [33] and highlights the importance of studying not only specific antibody levels but also functionality of immune responses to not miss any potential correlate.
Importantly, correlates of protection were identified only when accounting for heterogeneity in malaria exposure by (a) including only malaria-exposed individuals and (b) considering different exposure levels by clinical, serological and demographic data. By doing so, the effect of heterogeneous malaria exposure was reduced, and therefore correlates of protection could be identified. Limiting the follow-up time did not have an impact on our conclusions when considering malaria exposure, probably by the longer maintenance of protective immunity in malaria-exposed population, although this approach was shown useful when exposure variables were not available. This will happen in low transmission contexts where malaria exposure will be more difficult to define due to the expected drop in clinical episodes.
This study has some limitations. First, truly exposed individuals could be excluded from the analysis, given the restrictive definition of exposure used and the lack of serological data after 24 months. In this line, the PCD and OM methodologies can lead to underestimate the exposed population. However, the study area has an established DSS that allowed a rigorous and complete documentation of clinical malaria cases over the study period. Furthermore, our definition of malaria-exposure included clinical, parasitological, and serological markers (IgMs). Another potential limitation is the methodology to control the follow-up time. Given that protective thresholds are unknown, the time to 25% of baseline maternal antibody levels was arbitrarily selected to allow antibodies to decrease while remaining higher than the seropositivity cutoff. Other limitations include a lacking evaluation of combination of antibody responses associated with malaria risk and of functional immunity, which needs to be further studied in bigger populations, with a larger panel of antigens and including subclasses characterization [32, 33, 39, 40] . This will provide enough statistical power to identify, if any, more correlates of protection, because unfortunately, availability of samples was limited.
Altogether, we report new correlates of clinical malaria protection and the importance of age in these studies. We also confirm the crucial requirement to account for heterogeneity in malaria exposure during vaccine development: from the identification of candidates to the evaluation of its efficacy. This need will become more apparent as malaria transmission drops, because the probability of including malaria-unexposed population in clinical trials will increase.
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